Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early …GlobeNewswire (press release)The Providence Cancer Institute translational medicine team conducted two phase 1 clinical trials, initiated under d… Continue reading
|
International Stem Cell Corporation Announces Positive Interim Clinical Results for Parkinson’s Disease Clinical Trial
GlobeNewswire (press release) CARLSBAD, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the … |
|
CRISPR Therapeutics (CRSP) Names Michael Tomsicek as CFO
StreetInsider.com CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the appointment of Michael Tomsicek as Chief Financial Officer. Mr. Tomsicek is a highly … Equities Analysts Offer Predictions for Crispr Theraptc’s FY2017 Earnings (CRSP)Dispatch Tribunal Head to Head Analysis: Crispr Theraptc (CRSP) versus The CompetitionWeek Herald Crispr Theraptc (CRSP) Receives Hold Rating from SunTrust Banks, Inc.BBNS Analyst Ratings all 13 news articles » |